LeuTech Studies In Neutropenic Patients Suggested By FDA Committee
Executive Summary
Palatin and co-development partner Mallinckrodt should conduct studies with LeuTech to verify efficacy in neutropenic patients and to ensure that the radiolabeled monoclonal antibody imaging agent does not damage white blood cells, FDA's Medical Imaging Drugs Advisory Committee suggested during a July 10 meeting.